Search | Clinical Trials Finder

Conditions: Schizophrenia
Interventions: Quetiapine, Risperidone, Fluphenazine; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Catonsville, Maryland

Conditions: Bipolar II Disorder
Interventions: Quetiapine/Seroquel, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Parkinson's Disease Psychosis
Interventions: Pimavanserin, Quetiapine; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years and older
Enrollment: 358 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 24
States / cities: Tucson, Arizona • Loma Linda, California • Palo Alto, California + 20 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: quetiapine, haloperidol decanoate; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Aripiprazole, Olanzapine, Paliperidone, Quetiapine, Risperidone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Torrance, California • Kissimmee, Florida • Conshohocken, Pennsylvania

Conditions: Bipolar Disorder
Interventions: Lithium, Quetiapine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 68 Years
Enrollment: 482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 11
States / cities: Birmingham, Alabama • Stanford, California • Boston, Massachusetts + 8 more

Conditions: Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
Interventions: Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, Risperidone, LAI; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 6
States / cities: Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: quetiapine fumarate, risperidone; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,098 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 63
States / cities: Little Rock, Arkansas • Mabelvale, Arkansas • Morrilton, Arkansas + 60 more

Conditions: Apathy, Schizophrenia, Schizophrenia; Psychosis
Interventions: Lumateperone 42 mg, Risperidone 2 mg; Drug
Lead sponsor: Louisiana State University Health Sciences Center Shreveport; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Schizophrenia
Interventions: ASP4345, placebo, risperidone, quetiapine, olanzapine, ziprasidone, aripiprazole, brexpiprazole, paliperidone, lurasidone; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 27
States / cities: Cerritos, California • Garden Grove, California • Lemon Grove, California + 19 more

Conditions: Parkinson's Disease
Interventions: Pimavanserin, Placebo, Quetiapine; Drug · Other
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 16
States / cities: Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 13 more

Conditions: Cocaine Dependence, Cocaine Abuse, Cocaine Addiction, Drug Abuse, Substance Abuse
Interventions: quetiapine fumarate, Matched Placebo, Cognitive-behavioral Therapy; Drug · Behavioral
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Schizophrenia
Interventions: Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate, Chlorpromazine, Droperidol, Fluphenazine, Haloperidol, Loxapine, Perphenazine, Pimozide, Prochlorperazine, Thiothixene, Thioridazine, Trifluoperazine, Aripiprazole, Asenapine, Clozapine, Iloperidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone; Other · Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 34
States / cities: Bullhead City, Arizona • Oceanside, California • Denver, Colorado + 31 more

Conditions: Alcoholism, Anxiety Disorders, Generalized Anxiety Disorder, Post-Traumatic Stress Disorder, Panic Disorder, Obsessive-Compulsive Disorder
Interventions: Seroquel XR; Drug
Lead sponsor: Creighton University; Other
Eligibility: 19 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: risperidone, quetiapine; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 7
States / cities: San Diego, California • Hoffman Est, Illinois • Lake Charles, Louisiana + 4 more

Conditions: Bipolar I Disorder
Interventions: Injectable Risperidone (Consta) or oral antipsychotic; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 4
States / cities: Bridgeville, Pennsylvania • DuBois, Pennsylvania • McKeesport, Pennsylvania + 1 more

Conditions: Schizophrenia
Interventions: SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole); Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Dayton, Ohio + 1 more

Conditions: Bipolar Disorder
Interventions: quetiapine fumarate; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 32
States / cities: Scottsdale, Arizona • Riverside, California • Sacramento, California + 29 more

Conditions: Schizophrenia
Interventions: Bifeprunox, Quetiapine; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 69
States / cities: Anaheim, California • Cerritos, California • Costa Mesa, California + 52 more

Conditions: Alzheimer's Disease
Interventions: Olanzapine, Quetiapine, Risperidone, Citalopram; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 34
States / cities: Tuscaloosa, Alabama • Irvine, California • Los Angeles, California + 29 more

Conditions: Bipolar Disorder
Interventions: Lithium Carbonate, Lamotrigine, Valproic Acid, Oxcarbazepine, Carbamazepine, Ziprasidone, Risperidone, Quetiapine, Olanzapine, Aripiprazole, Fluoxetine / Olanzapine, Haloperidol, Perphenazine, Clozapine, Asenapine, Lurasidone, Paliperidone, Mirtazapine, Bupropion, Desvenlafaxine, Duloxetine, Venlafaxine, Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Doxepin; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: Not listed
Enrollment: 1,037,352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Major Depressive Disorder
Interventions: Levomilnacipran, Quetiapine; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Alpharetta, Georgia

Conditions: Bipolar Disorder, Bipolar Depression, Depression
Interventions: quetiapine fumarate (Seroquel), paroxetine, mood stabilizing activity; Drug · Behavioral
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 676 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 28
States / cities: Phoenix, Arizona • Little Rock, Arkansas • National City, California + 25 more

Conditions: Bipolar Disorder
Interventions: Standard of Care, Ketamine, D-cycloserine; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia

Seroquel in the Treatment of Dysphoric Hypomania in Bipolar II

Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder

A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

Comparative Effectiveness Study for Bipolar Disorder

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder

Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine

Quetiapine for the Reduction of Cocaine Use

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety

Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder

Risperdal Consta for Bipolar Disorder

A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia

Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Children & Adolescents With Bipolar I Mania

Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients

CATIE-Alzheimer's Disease Trial

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD

Seroquel in Bipolar Depression Versus SSRI

NMDA Antagonists in Bipolar Depression